Insomnia

Pear Therapeutics Seeks Approval for Rx Digital Therapeutic to Treat Insomnia, Depression

Pear Therapeutics is seeking marketing authorization from the Food and Drug Administration (FDA) for Somryst, a prescription digital therapeutic (PDT) intended for use in the treatment of adults with chronic insomnia and depression.  Somryst works by reducing symptoms of depression and the severity of insomnia through neurobehavioral interventions, specifically cognitive behavioral therapy for insomnia (CBTi)…